G

Genflow Biosciences plc (GENFF)

OQB – Real Time Price. Currency in USD

0.06

+0.02 (52.09%)

At close: Sep 8, 2026, 4:00 PM EDT

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Genflow Biosciences plc (GENFF)

OQB – Real Time Price. Currency in USD

0.06

+0.02 (52.09%)

At close: Sep 8, 2026, 4:00 PM EDT

08.09.2026

Genflow's gene therapy hits key trial goal in ageing dogs

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) the London-listed biotechnology company developing gene therapies for age-related diseases, announced on Tuesday that its SLAB clinical trial had met its primary endpoint. The trial, known formally as Sarcopenia and Longevity in Aged Beagles, tested the company's SIRT6 centenarian gene therapy in 24 dogs aged over ten.

08.09.2026

Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

07.09.2026

Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser

LONDON, UK / ACCESS Newswire / September 7, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, today announces the appointment of ON365 Partners Inc. ("ON365") as the Company's investor relations adviser, with immediate effect. ON365 succeeds Harbor Access, which has supported the Company's investor relations activities to date.

03.08.2026

Genflow wins fast-track US examination for foundational longevity patent

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the London-listed longevity research company, said the United States Patent and Trademark Office had granted accelerated examination for the foundational patent application covering its centenarian-derived gene variant. The Track One status speeds up assessment of the application, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases", though it does not guarantee a grant or determine what claims are eventually allowed.

03.08.2026

Genflow Biosciences PLC Announces Patent Update

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

Videos

No Data

There is no data to display

Press releases

08.09.2026

Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

07.09.2026

Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser

LONDON, UK / ACCESS Newswire / September 7, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, today announces the appointment of ON365 Partners Inc. ("ON365") as the Company's investor relations adviser, with immediate effect. ON365 succeeds Harbor Access, which has supported the Company's investor relations activities to date.

03.08.2026

Genflow Biosciences PLC Announces Patent Update

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

Search stocks

Genflow Biosciences plc (GENFF)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Genflow Biosciences plc (GENFF)

Genflow's gene therapy hits key trial goal in ageing dogs

Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met

Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser

Genflow wins fast-track US examination for foundational longevity patent

Genflow Biosciences PLC Announces Patent Update

Videos

No Data

Press releases

Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met

Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser

Genflow Biosciences PLC Announces Patent Update